艾隆科技2025年三季报显示，前三季度公司主营收入2.8亿元，同比上升25.12%；归母净利润-95.89万 元，同比上升96.56%；扣非净利润-1146.72万元，同比上升66.35%；其中2025年第三季度，公司单季度 主营收入1.49亿元，同比上升83.53%；单季度归母净利润743.13万元，同比上升182.09%；单季度扣非 净利润662.45万元，同比上升160.26%；负债率42.74%，投资收益-424.88万元，财务费用468.61万元， 毛利率45.79%。艾隆科技（688329）主营业务：公司专注于医疗物资的智能管理领域,通过打造医疗物 资智能管理设备及软件信息平台,为各级医疗服务机构提供医疗物资智能化管理整体解决方案。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向 ...

Core Viewpoint - On November 21, Ailong Technology experienced a decline of 4.95% with a trading volume of 48.73 million yuan, indicating a potential market reaction to recent financial performance and investor sentiment [1] Financing Summary - On the same day, Ailong Technology had a financing purchase amount of 7.44 million yuan and a financing repayment of 2.52 million yuan, resulting in a net financing purchase of 4.91 million yuan [1] - As of November 21, the total financing and securities lending balance for Ailong Technology was 57.79 million yuan, which accounts for 3.51% of its market capitalization, indicating a low financing balance compared to the 20th percentile over the past year [1] - There were no shares repaid or sold in the securities lending market on November 21, with a total securities lending balance of 0.00 yuan, suggesting a high level of inactivity in this area compared to the 90th percentile over the past year [1] Company Overview - Ailong Technology, established on January 20, 2006, and listed on March 29, 2021, focuses on intelligent management of medical supplies, providing comprehensive solutions through smart management devices and software platforms for healthcare institutions [2] - The company's revenue composition includes: smart emergency pharmacy products (43.34%), maintenance services (16.55%), inpatient and infusion center products (16.03%), and other categories [2] - As of September 30, the number of shareholders was 5,144, a decrease of 4.99%, while the average circulating shares per person increased by 5.25% to 15,007 shares [2] Financial Performance - For the period from January to September 2025, Ailong Technology reported a revenue of 280 million yuan, reflecting a year-on-year growth of 25.12%, while the net profit attributable to the parent company was -0.96 million yuan, showing a significant year-on-year improvement of 96.56% [2] Dividend Information - Since its A-share listing, Ailong Technology has distributed a total of 111 million yuan in dividends, with 49.05 million yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the sixth largest circulating shareholder of Ailong Technology was the Dacheng CSI 360 Internet + Index A (002236), holding 741,700 shares, which is a decrease of 86,500 shares compared to the previous period [3]

Group 1 - The core point of the news is that Ailong Technology's stock price has dropped by 5.04%, currently trading at 21.31 CNY per share, with a total market capitalization of 1.645 billion CNY [1] - Ailong Technology, established on January 20, 2006, focuses on intelligent management of medical supplies, providing comprehensive solutions through smart management devices and software platforms for healthcare institutions [1] - The company's main revenue sources include smart emergency pharmacy products (43.34%), maintenance services (16.55%), inpatient and infusion center products (16.03%), and other categories [1] Group 2 - Among Ailong Technology's top circulating shareholders, Dacheng Fund's index fund has reduced its holdings by 86,500 shares, now holding 741,700 shares, which is 0.96% of the circulating shares [2] - The Dacheng Zhongzheng 360 Internet + Index A fund has achieved a year-to-date return of 38.22% and a one-year return of 39.52%, ranking 871 out of 4208 and 577 out of 3972 respectively [2]

Group 1 - The core point of the news is that Ailong Technology's stock price dropped by 5.14% to 20.13 CNY per share, with a total market capitalization of 1.554 billion CNY as of the report date [1] - Ailong Technology, established on January 20, 2006, focuses on intelligent management of medical supplies, providing comprehensive solutions through smart management devices and software platforms for healthcare institutions [1] - The company's revenue composition includes: smart emergency pharmacy products (43.34%), maintenance services (16.55%), inpatient and infusion center products (16.03%), and other categories [1] Group 2 - Among the top circulating shareholders of Ailong Technology, the Dachen Zhongzheng 360 Internet + Index A fund holds 828,300 shares, accounting for 1.07% of circulating shares, with an estimated floating loss of approximately 902,800 CNY [2] - The Dachen Zhongzheng 360 Internet + Index A fund, established on February 3, 2016, has a current scale of 698 million CNY and has achieved a year-to-date return of 34.45% [2] - The fund manager, Xia Gao, has a tenure of nearly 11 years, with the best fund return during this period being 215.74% [3]

Group 1 - The core business of Ailong Technology focuses on intelligent management of medical supplies, providing comprehensive solutions through smart management devices and software platforms for medical institutions [2] - As of August 8, 2025, the number of shareholders in Ailong Technology increased by 3.45% to 4,711, while the average circulating shares per person decreased by 3.33% to 16,387 shares [2] - For the first half of 2025, Ailong Technology reported a revenue of 131 million yuan, a year-on-year decrease of 8.11%, and a net profit attributable to shareholders of -8.39 million yuan, an increase of 55.47% year-on-year [2] Group 2 - Ailong Technology has distributed a total of 111 million yuan in dividends since its A-share listing, with 49.05 million yuan distributed over the past three years [3] - As of June 30, 2025, the sixth largest circulating shareholder of Ailong Technology is Dazheng Zhongzheng 360 Internet+ Index A, holding 828,300 shares as a new shareholder [3] Group 3 - On August 26, Ailong Technology's stock price increased by 0.40%, with a trading volume of 41.91 million yuan [1] - The financing buy-in amount for Ailong Technology on August 26 was 4.86 million yuan, with a net financing buy-in of 643,800 yuan, while the total financing and securities balance reached 68.61 million yuan, accounting for 3.92% of the circulating market value [1] - The securities lending data for Ailong Technology on August 26 showed no shares were lent or repaid, indicating a high level of securities lending balance at 0.00 shares, which is above the 90th percentile over the past year [1]

Group 1 - The core business of Suzhou Ailong Technology Co., Ltd. focuses on intelligent management of medical supplies, providing comprehensive solutions for medical institutions [1] - The company's main products include automated pharmacies, automated wards, and automated logistics [1] - As of the first quarter of 2025, the company reported revenue of 56.068 million yuan, a year-on-year increase of 0.44%, and a net profit of -14.166 million yuan, a year-on-year decrease of 1.42%, with a gross profit margin of 42.75% [1] Group 2 - Ailong Technology's latest closing price was 17.12 yuan, up 1.97%, with a market-to-book ratio of 1.79, marking a new low in 44 days, and a total market capitalization of 1.322 billion yuan [1] - As of the first quarter of 2025, there are four institutional holders of Ailong Technology, including three other entities and one fund, holding a total of 3.3392 million shares valued at 5.1 million yuan [1] - The company's PE (TTM) is -60.35, while the industry average PE is 62.88, indicating a significant divergence from industry performance [2]

Group 1 - The core business of Suzhou Ailong Technology Co., Ltd. focuses on intelligent management of medical supplies, providing comprehensive solutions for various medical service institutions [1][2] - The company has received multiple honors, including "National Torch Program Key High-tech Enterprise" and "Top Ten Medical Equipment Suppliers in China Hospital Construction" [1] - As of the first quarter of 2025, the company reported a revenue of 56.068 million yuan, with a year-on-year growth of 0.44%, and a net profit of -14.166 million yuan, reflecting a year-on-year decline of 1.42% [2] Group 2 - The latest market performance shows Ailong Technology's stock closed at 16.47 yuan, up 1.67%, with a market capitalization of 1.271 billion yuan [1] - The company has a price-to-earnings (PE) ratio of -58.05 and a price-to-book (PB) ratio of 1.72, compared to the industry average PE of 61.40 and PB of 4.26 [2] - As of the first quarter of 2025, four institutions held shares in Ailong Technology, with a total holding of 3.3392 million shares valued at 0.051 billion yuan [1][2]